308 related articles for article (PubMed ID: 31292160)
1. Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells.
Wu X; Yeerna H; Goto Y; Ando T; Wu VH; Zhang X; Wang Z; Amornphimoltham P; Murphy AN; Tamayo P; Chen Q; Lippman SM; Gutkind JS
Cancer Res; 2019 Sep; 79(17):4360-4370. PubMed ID: 31292160
[TBL] [Abstract][Full Text] [Related]
2. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
Madera D; Vitale-Cross L; Martin D; Schneider A; Molinolo AA; Gangane N; Carey TE; McHugh JB; Komarck CM; Walline HM; William WN; Seethala RR; Ferris RL; Gutkind JS
Cancer Prev Res (Phila); 2015 Mar; 8(3):197-207. PubMed ID: 25681087
[TBL] [Abstract][Full Text] [Related]
3. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
[TBL] [Abstract][Full Text] [Related]
4. Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway.
Wu TK; Ou YC; Chen YP; Huang FM; Pan YR; Lee CJ
Anticancer Res; 2021 Aug; 41(8):3789-3799. PubMed ID: 34281838
[TBL] [Abstract][Full Text] [Related]
5. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor.
Gorur A; Patiño M; Shi T; Corrales G; Takahashi H; Rangel R; Gleber-Netto FO; Pickering C; Myers JN; Cata JP
J Cell Physiol; 2021 Nov; 236(11):7698-7710. PubMed ID: 34038587
[TBL] [Abstract][Full Text] [Related]
6. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
[TBL] [Abstract][Full Text] [Related]
7. Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Crist M; Yaniv B; Palackdharry S; Lehn MA; Medvedovic M; Stone T; Gulati S; Karivedu V; Borchers M; Fuhrman B; Crago A; Curry J; Martinez-Outschoorn U; Takiar V; Wise-Draper TM
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328378
[TBL] [Abstract][Full Text] [Related]
8. Dynamic cellular and molecular modulations of diabetes mediated head and neck carcinogenesis.
Liu CJ; Chang WJ; Chen CY; Sun FJ; Cheng HW; Chen TY; Lin SC; Li WC
Oncotarget; 2015 Oct; 6(30):29268-84. PubMed ID: 26337468
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cells enrichment with surface markers CD271 and CD44 in human head and neck squamous cell carcinomas.
Elkashty OA; Abu Elghanam G; Su X; Liu Y; Chauvin PJ; Tran SD
Carcinogenesis; 2020 Jun; 41(4):458-466. PubMed ID: 31742606
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of organic cation transporter OCT-3 in oral premalignant and malignant lesions: potential implications in the antineoplastic effects of metformin.
Patel H; Younis RH; Ord RA; Basile JR; Schneider A
J Oral Pathol Med; 2013 Mar; 42(3):250-6. PubMed ID: 22861817
[TBL] [Abstract][Full Text] [Related]
11. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
[TBL] [Abstract][Full Text] [Related]
12. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
Xie J; Li Q; Ding X; Gao Y
Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.
Liu C; Sadat SH; Ebisumoto K; Sakai A; Panuganti BA; Ren S; Goto Y; Haft S; Fukusumi T; Ando M; Saito Y; Guo T; Tamayo P; Yeerna H; Kim W; Hubbard J; Sharabi AB; Gutkind JS; Califano JA
Clin Cancer Res; 2020 Jun; 26(11):2693-2703. PubMed ID: 31932491
[TBL] [Abstract][Full Text] [Related]
14. Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.
Lin YC; Wu MH; Wei TT; Lin YC; Huang WC; Huang LY; Lin YT; Chen CC
Oncotarget; 2014 Jan; 5(1):298-308. PubMed ID: 24457597
[TBL] [Abstract][Full Text] [Related]
15. MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma.
Berggren KL; Restrepo Cruz S; Hixon MD; Cowan AT; Keysar SB; Craig S; James J; Barry M; Ozbun MA; Jimeno A; McCance DJ; Beswick EJ; Gan GN
Oncogene; 2019 Nov; 38(48):7329-7341. PubMed ID: 31417185
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
Keysar SB; Le PN; Miller B; Jackson BC; Eagles JR; Nieto C; Kim J; Tang B; Glogowska MJ; Morton JJ; Padilla-Just N; Gomez K; Warnock E; Reisinger J; Arcaroli JJ; Messersmith WA; Wakefield LM; Gao D; Tan AC; Serracino H; Vasiliou V; Roop DR; Wang XJ; Jimeno A
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
[TBL] [Abstract][Full Text] [Related]
17. Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma.
Hu Q; Peng J; Jiang L; Li W; Su Q; Zhang J; Li H; Song M; Cheng B; Xia J; Wu T
Cell Death Dis; 2020 Oct; 11(10):925. PubMed ID: 33116117
[TBL] [Abstract][Full Text] [Related]
18. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
Amornphimoltham P; Patel V; Leelahavanichkul K; Abraham RT; Gutkind JS
Cancer Res; 2008 Feb; 68(4):1144-53. PubMed ID: 18281490
[TBL] [Abstract][Full Text] [Related]
19. LOXL2-enriched small extracellular vesicles mediate hypoxia-induced premetastatic niche and indicates poor outcome of head and neck cancer.
Zhu G; Wang L; Meng W; Lu S; Cao B; Liang X; He C; Hao Y; Du X; Wang X; Li L; Li L
Theranostics; 2021; 11(19):9198-9216. PubMed ID: 34646366
[TBL] [Abstract][Full Text] [Related]
20. 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer.
Wang Z; Feng X; Molinolo AA; Martin D; Vitale-Cross L; Nohata N; Ando M; Wahba A; Amornphimoltham P; Wu X; Gilardi M; Allevato M; Wu V; Steffen DJ; Tofilon P; Sonenberg N; Califano J; Chen Q; Lippman SM; Gutkind JS
Cancer Res; 2019 Apr; 79(7):1438-1450. PubMed ID: 30894372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
